<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03128281</url>
  </required_header>
  <id_info>
    <org_study_id>2015-0973</org_study_id>
    <secondary_id>NCI-2018-01330</secondary_id>
    <nct_id>NCT03128281</nct_id>
  </id_info>
  <brief_title>Pneumoperitoneum Management With Low vs. Higher Pressure</brief_title>
  <official_title>A Single Center, Prospective, Randomized, Controlled Study to Evaluate Shoulder Pain, Cardiovascular Changes, Pulmonary Pressures and Perioperative Outcomes Related to the Use of the AirSeal® Insufflation System (AIS) at Low and Higher Pressure Pneumoperitoneum vs. Conventional Insufflation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ConMed Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to compare the level of pain 2 hours after&#xD;
      surgery in patients after the use of the AirSeal® Insufflation System (AIS) at a high or low&#xD;
      pressure setting or the standard insufflator (the conventional insufflation system, or CIS).&#xD;
      &quot;Insufflation&quot; is the creation of a pressure barrier of air/gas within the abdomen that&#xD;
      allows the surgeon more space to work in.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Baseline Visit:&#xD;
&#xD;
      If participant agrees to take part in this study, within 30 days before surgery, participant&#xD;
      will be asked to complete a questionnaire about participant's pain level and any drugs&#xD;
      participant may be taking for it. It should take about 5 minutes to complete.&#xD;
&#xD;
      Study Groups:&#xD;
&#xD;
      Participant will be randomly assigned to 1 of 3 groups (as in a roll of dice). This is done&#xD;
      because no one knows if one study group is better, the same, or worse than the other group.&#xD;
      Participant has an equal chance of being placed in each group. Participant will not know&#xD;
      which group participant is assigned to.&#xD;
&#xD;
        -  If participant is in Group 1, participant will have the CIS used during surgery.&#xD;
&#xD;
        -  If participant is in Group 2, participant will have the AIS used at a lower pressure&#xD;
           during surgery.&#xD;
&#xD;
        -  If participant is in Group 3, participant will have the AIS used at a higher pressure&#xD;
           during surgery.&#xD;
&#xD;
      Surgery:&#xD;
&#xD;
      Participant will then have surgery. Participant will sign a separate consent for the surgery&#xD;
      that explains the procedure, the risks of the surgery, and the risks of CIS.&#xD;
&#xD;
      Blood (about 3 teaspoons each time) will be collected 1 time before surgery, 2 times during&#xD;
      surgery, and 1 time after surgery is completed. Routine tests and tests to learn how&#xD;
      participant's body reacts to inflammation will be performed on this blood.&#xD;
&#xD;
      Questionnaires:&#xD;
&#xD;
      After surgery, participant will complete the questionnaire about participant's pain level and&#xD;
      any drugs participant is taking. Participant will complete this questionnaire:&#xD;
&#xD;
        -  Two (2) hours after surgery,&#xD;
&#xD;
        -  When participant leaves the post-anesthesia care unit (PACU), and&#xD;
&#xD;
        -  When participant is discharged from the hospital&#xD;
&#xD;
      If participant is discharged the same day as participant's surgery, participant will be&#xD;
      called by the study staff to answer the questionnaire the following day.&#xD;
&#xD;
      Length of Study Participation:&#xD;
&#xD;
      Participation in the study will be over after participant completes the questionnaire after&#xD;
      participant is discharged, unless participant agrees to complete additional optional&#xD;
      questionnaires.&#xD;
&#xD;
      This is an investigational study. Both AirSeal® insufflation system (AIS) and conventional&#xD;
      insufflation systems (CIS) are FDA approved and commercially available. It is investigational&#xD;
      to compare the effects of high and low pressures using the AIS.&#xD;
&#xD;
      Up to 240 participants will be enrolled in this study. All will take part at MD Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Sponsor issue&#xD;
  </why_stopped>
  <start_date type="Anticipated">July 2018</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Shoulder Pain After Laparoscopic/Robotic Surgery</measure>
    <time_frame>Post-operative day 1</time_frame>
    <description>Incidence of shoulder pain defined by a positive (&gt;0) score for an 11-point pain intensity numeric rating scale (PI-NRS).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Malignant Neoplasms of Female Genital Organs</condition>
  <arm_group>
    <arm_group_label>Conventional Insufflation System (CIS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Questionnaires completed 30 days before surgery, two (2) hours after surgery, when leaving the post-anesthesia care unit (PACU), and at hospital discharge.&#xD;
Conventional Insufflation System (CIS) used for pneumoperitoneum during laparoscopic/robotic surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ConMed AirSeal Insufflation System (AIS) at Low Pressure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Questionnaires completed 30 days before surgery, two (2) hours after surgery, when leaving the post-anesthesia care unit (PACU), and at hospital discharge.&#xD;
ConMed AirSeal Insufflation System (AIS) at Low Pressure used for pneumoperitoneum during laparoscopic/robotic surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ConMed AirSeal Insufflation System (AIS) at Higher Pressure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Questionnaires completed 30 days before surgery, two (2) hours after surgery, when leaving the post-anesthesia care unit (PACU), and at hospital discharge.&#xD;
ConMed AirSeal Insufflation System (AIS) at Higher Pressure used for pneumoperitoneum during laparoscopic/robotic surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>Questionnaires completed 30 days before surgery, two (2) hours after surgery, when leaving the post-anesthesia care unit (PACU), and at hospital discharge.&#xD;
Questionnaires ask about pain level and any drugs taken for it. It should take about 5 minutes to complete.</description>
    <arm_group_label>ConMed AirSeal Insufflation System (AIS) at Higher Pressure</arm_group_label>
    <arm_group_label>ConMed AirSeal Insufflation System (AIS) at Low Pressure</arm_group_label>
    <arm_group_label>Conventional Insufflation System (CIS)</arm_group_label>
    <other_name>Surveys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Conventional Insufflation System (CIS)</intervention_name>
    <description>CIS with pressure target of 15±1 mmHg used for pneumoperitoneum during laparoscopic/robotic surgery.</description>
    <arm_group_label>Conventional Insufflation System (CIS)</arm_group_label>
    <other_name>CIS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ConMed AirSeal Insufflation System (AIS) at Low Pressure</intervention_name>
    <description>AIS with an insufflation pressure target of 9±1 mmHg used for pneumoperitoneum during laparoscopic/robotic surgery.</description>
    <arm_group_label>ConMed AirSeal Insufflation System (AIS) at Low Pressure</arm_group_label>
    <other_name>AIS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ConMed AirSeal Insufflation System (AIS) at Higher Pressure</intervention_name>
    <description>AIS with an insufflation pressure target of 15±1 mmHg used for pneumoperitoneum during laparoscopic/robotic surgery.</description>
    <arm_group_label>ConMed AirSeal Insufflation System (AIS) at Higher Pressure</arm_group_label>
    <other_name>AIS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. All gynecologic laparoscopic/robotic surgeries EXCEPT diagnostic laparoscopies&#xD;
&#xD;
          2. 18-80 years of age&#xD;
&#xD;
          3. Capable and willing to provide Informed consent&#xD;
&#xD;
          4. Acceptable candidate for laparoscopic/robotic GYN surgery as per discretion of the&#xD;
             surgeon&#xD;
&#xD;
          5. If patient agrees to participate in the optional patient reported outcomes portion of&#xD;
             the study, patient must be English speaking and willing to complete the MD Anderson&#xD;
             Symptom Inventory (MDASI) questionnaires&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active cutaneous infection or inflammation&#xD;
&#xD;
          2. Pre-existing active or untreated immunodeficiency disorder and/or chronic use of&#xD;
             systemic steroids&#xD;
&#xD;
          3. Uncontrolled diabetes mellitus&#xD;
&#xD;
          4. Severe co-existing morbidities having a life expectancy of less than 30 days&#xD;
&#xD;
          5. Significant anemia with hemoglobin level less than 7 g/dL or a hematocrit less than&#xD;
             21%&#xD;
&#xD;
          6. Females who are pregnant or lactating&#xD;
&#xD;
          7. Patients presenting with ascites&#xD;
&#xD;
          8. Patients with Chronic Pain Syndrome or requiring/using chronic pain medications&#xD;
&#xD;
          9. Patients undergoing diagnostic laparoscopy&#xD;
&#xD;
         10. Patients planning to undergo hand-assisted laparoscopy&#xD;
&#xD;
         11. Severe comorbidities (atrial fibrillation, pulmonary hypertension, etc...)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro T. Ramirez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 20, 2017</study_first_submitted>
  <study_first_submitted_qc>April 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2017</study_first_posted>
  <last_update_submitted>May 29, 2019</last_update_submitted>
  <last_update_submitted_qc>May 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malignant Neoplasms of Female Genital Organs</keyword>
  <keyword>Laparoscopic gynecologic surgery</keyword>
  <keyword>Robotic gynecologic surgery</keyword>
  <keyword>AirSeal® Insufflation System</keyword>
  <keyword>AIS</keyword>
  <keyword>Conventional Insufflation System</keyword>
  <keyword>CIS</keyword>
  <keyword>Questionnaires</keyword>
  <keyword>Surveys</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Genital Neoplasms, Female</mesh_term>
    <mesh_term>Pneumoperitoneum</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

